Hydrochloric Acid → (S)-2-(methyl(4-(5-(morpholin-2-ylmethylamino)pyrido[4,3-b]pyrazin-7-yl)phenyl)amino)ethanol
반응식
[OH:1][CH2:2][CH2:3][N:4]([CH3:36])[C:5]1[CH:10]=[CH:9][C:8]([C:11]2[N:20]=[C:19]([NH:21][CH2:22][C@H:23]3[O:28][CH2:27][CH2:26][N:25](C(OC(C)(C)C)=O)[CH2:24]3)[C:18]3[C:13](=[N:14][CH:15]=[CH:16][N:17]=3)[CH:12]=2)=[CH:7][CH:6]=1.Cl>CC(=O)OCC>[CH3:36][N:4]([C:5]1[CH:6]=[CH:7][C:8]([C:11]2[N:20]=[C:19]([NH:21][CH2:22][C@H:23]3[O:28][CH2:27][CH2:26][NH:25][CH2:24]3)[C:18]3[C:13](=[N:14][CH:15]=[CH:16][N:17]=3)[CH:12]=2)=[CH:9][CH:10]=1)[CH2:3][CH2:2][OH:1]참가 물질
4
반응물 2
생성물 1
시약·촉매·용매 1
실험 절차
(R)-tert-butyl 2-((7-(4-((2-hydroxyethyl)(methyl)amino)phenyl)pyrido[4,3-b]pyrazin-5-ylamino)methyl)morpholine-4-carboxylate was dissolved in EA (20 mL), 5M HCl in EA (10 mL) was added, the mixture was stirred at room temperature overnight. It was concentrated, treated with NH3.H2O, concentrated, purified by preparative TLC to give 10 mg reddish-brown solid. MS (m/z): 395 (M+H)+